News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
257,595 Results
Type
Article (7719)
Company Profile (50)
Press Release (249826)
Section
Business (70292)
Career Advice (293)
Deals (16594)
Drug Delivery (38)
Drug Development (17987)
Employer Resources (36)
FDA (6616)
Job Trends (6326)
News (114531)
Policy (10694)
Tag
Academia (759)
Alliances (19182)
Alzheimer's disease (365)
Approvals (6604)
Artificial intelligence (69)
Bankruptcy (119)
Best Places to Work (5613)
Biosimilars (33)
Breast cancer (37)
Cancer (275)
Cardiovascular disease (30)
Career advice (268)
Cell therapy (41)
Clinical research (14697)
Collaboration (139)
COVID-19 (755)
C-suite (28)
Data (308)
Diabetes (51)
Diagnostics (3439)
Drug pricing (40)
Earnings (22752)
Employer resources (32)
Events (53217)
Executive appointments (116)
FDA (6809)
Funding (119)
Gene therapy (39)
GLP-1 (139)
Government (1458)
Healthcare (9608)
Infectious disease (782)
Inflammatory bowel disease (36)
Interviews (37)
IPO (8068)
Job creations (878)
Job search strategy (241)
Layoffs (78)
Legal (2369)
Lung cancer (46)
Manufacturing (46)
Medical device (7097)
Medtech (7097)
Mergers & acquisitions (8633)
Metabolic disorders (131)
Neuroscience (429)
NextGen Class of 2024 (3398)
Non-profit (1651)
Northern California (458)
Obesity (80)
Opinion (59)
People (22239)
Phase I (3652)
Phase II (5810)
Phase III (6157)
Pipeline (86)
Postmarket research (820)
Preclinical (1247)
Radiopharmaceuticals (106)
Rare diseases (57)
Real estate (1815)
Regulatory (7269)
Research institute (732)
Resumes & cover letters (28)
Southern California (399)
Startups (1531)
United States (4846)
Vaccines (111)
Weight loss (41)
Date
Today (107)
Last 7 days (361)
Last 30 days (1195)
Last 365 days (15272)
2024 (12833)
2023 (16972)
2022 (24395)
2021 (26530)
2020 (25915)
2019 (21239)
2018 (15859)
2017 (11951)
2016 (11875)
2015 (14382)
2014 (10412)
2013 (8607)
2012 (9074)
2011 (8733)
2010 (7255)
Location
Africa (240)
Arizona (63)
Asia (13384)
Australia (1762)
California (1000)
Canada (402)
China (72)
Colorado (55)
Connecticut (51)
Europe (29162)
Florida (185)
Georgia (54)
Illinois (144)
Indiana (96)
Kansas (40)
Maine (51)
Maryland (158)
Massachusetts (817)
Michigan (90)
Minnesota (82)
New Jersey (369)
New York (392)
North Carolina (359)
Northern California (458)
Ohio (54)
Pennsylvania (346)
South America (344)
Southern California (399)
Texas (156)
Utah (57)
Washington State (104)
257,595 Results for "shionogi viiv healthcare llc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Infectious disease
GSK, ViiV Tout 99% Effectiveness for Long-Acting HIV PrEP as Gilead Gains Ground
Real-world evidence show that GSK and ViiV Healthcare’s long-acting pre-exposure prophylaxis Apretude can prevent nearly all HIV infections, while rival Gilead Sciences is moving quickly toward an approval for a twice-yearly option.
October 17, 2024
·
2 min read
·
Tristan Manalac
Bio NC
ViiV Healthcare and The American Academy of HIV Medicine Announce Fellowship to Improve HIV Prevention in Key Communities
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, and the American Academy of HIV Medicine jointly announced the launch of The Dr. Dawn K. Smith HIV Prevention Clinical Fellowship.
March 5, 2024
·
6 min read
Policy
ViiV Healthcare Announces Health Canada Approval for APRETUDE (Cabotegravir tablets and extended release injectable suspension) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi as shareholders, announced that Health Canada has granted approval for APRETUDE for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in at risk individuals who are HIV-1 negative.
May 13, 2024
·
10 min read
FDA
ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV.
April 8, 2024
·
10 min read
Drug Development
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from its phase I study showing that an investigational formulation of cabotegravir, known as cabotegravir ultra long-acting (CAB-ULA), can be dosed at intervals of at least four months.
March 4, 2024
·
7 min read
Business
Exavir Therapeutics Announces Entry Into a Litigation Settlement and License Agreement For Ultra-Long-Acting HIV Compounds With ViiV Healthcare
Today, Exavir Therapeutics announced that the company has entered into a settlement and license agreement with ViiV Healthcare for ultra-long-acting HIV compounds.
May 22, 2024
·
1 min read
WHO Warns of Growing Resistance in Individuals to GSK, ViiV’s HIV Drug Tivicay
The World Health Organization has detected signals of growing HIV resistance to GSK and ViiV Healthcare’s Tivicay, which it says must be minimized as part of the broader global response to antimicrobial resistance.
March 6, 2024
·
2 min read
·
Tristan Manalac
Press Releases
ViiV Healthcare Shows More Than 99% Effectiveness in Real-World Studies for Apretude (Cabotegravir Long-Acting), the Only Approved Long-Acting HIV PrEP, in Data Presented at IDWeek 2024
October 16, 2024
·
13 min read
ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV
ViiV Healthcare today announced the presentation of 64 abstracts that includes highlights of the company’s next-generation pipeline advancements, alongside data from its diverse portfolio of marketed HIV treatment and prevention options at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) being held in Denver, Colorado, from 3 – 6 March 2024.
February 28, 2024
·
30 min read
Bio NC
ViiV Healthcare announces new packaging option now available in the U.S. for Dovato (dolutegravir/lamivudine)
ViiV Healthcare announced Dovato is now available in a blister pack in the U.S. Dovato is approved as a complete regimen to treat HIV-1 infection in adults with no antiretroviral treatment history or to replace the current ARV regimen in those who are virologically suppressed on a stable ARV regimen with no history of treatment failure and no known resistance to any component of Dovato.
February 5, 2024
·
9 min read
1 of 25,760
Next